TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11419834

Group type: EXPERIMENTAL
Intervention: IFN-alpha-2A (subcutaneous injections)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Prednisolone enemas
Number of subjects: 32
Study: 9251875

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 124

Group type: COMPARATOR
Intervention: Oral sumatriptan
Number of subjects: 124
Study: 8334908

Group type: EXPERIMENTAL
Intervention: 1% sodium hyaluronate (Healon) - 14 patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2% hydroxypropylmethylcellulose (HPMC) - 10 patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Viscose - 10 patients
Number of subjects: 34
Study: 3816835

Group type: EXPERIMENTAL
Intervention: Labetalol (loading dose followed by slow intravenous infusion over six hours, then oral therapy for five days, adjusted to maintain systolic pressure 100-120 mmHg)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 166
Study: 29336835

Group type: COMPARATOR
Intervention: Standard treatment (77 Gy in 35 fractions)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Dose-escalated treatment (77 Gy in 35 fractions + integrated boost up to 95 Gy)
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 571
Study: 28237539

Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus panitumumab (n = 400)
Number of subjects: 800

Group type: COMPARATOR
Intervention: mFOLFOX6 plus bevacizumab (n = 400)
Number of subjects: 800
Study: 26374482

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle-based intervention for 24 months
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard stroke care (control)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle-based intervention
Number of subjects: 202
Study: 24278929

Group type: EXPERIMENTAL
Intervention: Osstem TSIII HA implants (4.5 or 5.0 mm diameter, 10 mm long)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Zimmer TSV implants (4.7 mm diameter, 10 mm long)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both implant systems
Number of subjects: 50
Study: 20299784

Group type: EXPERIMENTAL
Intervention: Breakfast cereals and bread types
Number of subjects: 27
Study: 18219661

Group type: EXPERIMENTAL
Intervention: Gefitinib (treatment)
Number of subjects: 736

Group type: COMPARATOR
Intervention: Zymed antibody (treatment)
Number of subjects: 736
Study: 15965818

Group type: EXPERIMENTAL
Intervention: Synovialitis score grading system
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Synovialitis score of 4 points and more
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Validation of synovialitis score by gene expression data
Number of subjects: 483
Study: 12186624

Group type: EXPERIMENTAL
Intervention: Bicalutamide monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicalutamide (alone or as an adjuvant)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade with bicalutamide
Number of subjects: 0
Study: 10351414

Group type: EXPERIMENTAL
Intervention: New medication for osteoarthritis
Number of subjects: 14

Group type: COMPARATOR
Intervention: Managed care organizations (MCOs)
Number of subjects: 14
Study: 7743286

Group type: EXPERIMENTAL
Intervention: 5% lignocaine ointment applied to the heel under an occlusive dressing for one hour before heel prick
Number of subjects: 30
Study: 2382096

Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 0
Study: 7138632

Group type: EXPERIMENTAL
Intervention: Potassium and magnesium aspartate (K + Mg Asp) - 7.2 g administered during a 24 h period prior to work
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Potassium and magnesium aspartate (K + Mg Asp)
Number of subjects: 7
Study: 30690128

Group type: EXPERIMENTAL
Intervention: Observation (no treatment)
Number of subjects: 183
Study: 30633959

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) 50 ppm for 24 hours
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (oxygen plus 50 ppm nitrogen) for 24 hours
Number of subjects: 76
Study: 28628363

Group type: EXPERIMENTAL
Intervention: Interventionist-guided weight loss program
Number of subjects: 246

Group type: COMPARATOR
Intervention: Self-guided weight loss program
Number of subjects: 246
Study: 26591552

Group type: EXPERIMENTAL
Intervention: Pioglitazone as part of combination therapy for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 50
Study: 23900134

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 0

Group type: COMPARATOR
Intervention: No TENS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional tasks
Number of subjects: 0
Study: 21528639

Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg (test formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference product (control)
Number of subjects: 0
Study: 19358416

Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with a cytotoxic platinum agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytotoxic agents alone
Number of subjects: 0
Study: 16534013

Group type: EXPERIMENTAL
Intervention: Gemfibrozil treatment
Number of subjects: 1061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1061
Study: 12507703

Group type: EXPERIMENTAL
Intervention: ADL 10‐0101 (peripherally selective KOR agonist)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 11198708

Group type: EXPERIMENTAL
Intervention: Brief advice and motivational enhancement in primary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary health evaluation in a detoxification unit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Case monitoring for alcoholics
Number of subjects: 0
Study: 9011784

Group type: EXPERIMENTAL
Intervention: Multiple-allergen immunotherapy (subcutaneous injections of a mixture of up to seven aeroallergen extracts)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections of placebo)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Multiple-allergen immunotherapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 8493012

Group type: EXPERIMENTAL
Intervention: Visual acuity testing
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Contrast sensitivity testing
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Color vision testing
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Visual field testing
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: MRI changes
Number of subjects: 448

Group type: COMPARATOR
Intervention: Clinical and MRI evidence of multiple sclerosis
Number of subjects: 448
Study: 3124427

Group type: EXPERIMENTAL
Intervention: Doxycycline (400 mg in a single dose)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Cefuroxime (1.5 g given twice with an 8-hour interval)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Both groups (Doxycycline and Cefuroxime)
Number of subjects: 199
Study: 30541221

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg) 20 min before anesthesia induction, followed by 0.2 μg·kg(‐1)·h(‐1) intraoperatively.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dexmedetomidine (0.1 μg·kg(‐1)·h(‐1)) plus sufentanil (0.025 μg·kg(‐1)·h(‐1)) for PCA in group D.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group (D).
Number of subjects: 100
Study: 25412051

Group type: EXPERIMENTAL
Intervention: Single ultrasound-guided regional nerve block of the lateral femoral cutaneous nerve (LFCN)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block with catheter placement and continuous infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Local anesthetic infiltration
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: All regional anesthesia groups (LFCN block and compartment block)
Number of subjects: 19
Study: 24694531

Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg Q2W
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg QM
Number of subjects: 307

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 23713082

Group type: EXPERIMENTAL
Intervention: BAY 94‐8862 (2.5, 5, or 10 mg once daily)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: BAY 94‐8862 (5-10 mg/day)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Spironolactone (25 or 50 mg/day)
Number of subjects: 392
Study: 20138976

Group type: EXPERIMENTAL
Intervention: Retention interval (RI) of 1.5, 3, 24 or 48 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate test after training
Number of subjects: 0
Study: 19132268

Group type: EXPERIMENTAL
Intervention: Agaricus sylvaticus fungus (30 mg/kg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 16629794

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Triamcinolone acetonide 0.1% ointment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Cetomacrogol ointment (placebo)
Number of subjects: 8
Study: 14636982

Group type: COMPARATOR
Intervention: Artesunate alone (50 mg rectal capsules, 40 mg/kg total dose over 6 days)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Artesunate (50 mg rectal capsules, 30 mg/kg total dose for 3 days) + Mefloquine (20 mg/kg total dose on day 1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Artesunate (50 mg rectal capsules, 30 mg/kg total dose for 3 days) + Mefloquine (15-17 mg/kg total dose on days 1 and 3)
Number of subjects: 150
Study: 10933177

Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cells (PBSC)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Bone marrow
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CD34-selected PBSC
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: PBSC
Number of subjects: 108
Study: 8672384

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine and adrenaline 1/200,000 (B+E) 8 ml before incision and saline 8 ml after incision
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Saline 8 ml before incision and B+E 8 ml after incision
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline 8 ml before and after incision
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 45
Study: 2261385

Group type: EXPERIMENTAL
Intervention: Whole breast and regional lymph node areas radiotherapy (WF group)
Number of subjects: 708

Group type: COMPARATOR
Intervention: Radiotherapy to the affected quadrant only (LF group)
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Tumours histologically 1 cm or less in diameter
Number of subjects: 708

Group type: COMPARATOR
Intervention: Tumours measuring 2 cm or more in diameter
Number of subjects: 708
Study: 78446

Group type: EXPERIMENTAL
Intervention: Venom immunotherapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Whole-body extract
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30689969

Group type: EXPERIMENTAL
Intervention: Trial group with additional intraoperative splint for verification of implants' angulation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group with preplanned fibular reconstructions without additional splint
Number of subjects: 8
Study: 27690747

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 46
Study: 25325193

Group type: EXPERIMENTAL
Intervention: Web-based cultural competency training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Lecture-based cultural competency training
Number of subjects: 180
Study: 23192844

Group type: EXPERIMENTAL
Intervention: Mn‐supplemented diet
Number of subjects: 1

Group type: COMPARATOR
Intervention: Commercial diet
Number of subjects: 1
Study: 21812570

Group type: EXPERIMENTAL
Intervention: Theta-band activity over medial frontal scalp sites after negative feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-band activity after positive feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theta-band power
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-band power
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative feedback
Number of subjects: 0
Study: 19815402

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 14346
Study: 15804591

Group type: EXPERIMENTAL
Intervention: Acupuncture analgesia with general anaesthesia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acupuncture analgesia in addition to traditional postoperative analgesia
Number of subjects: 120
Study: 12858407

Group type: EXPERIMENTAL
Intervention: Anti-HCV treatment in HIV-coinfected patients
Number of subjects: 52
Study: 9796763

Group type: EXPERIMENTAL
Intervention: Colchicine treatment for 8 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo treatment for 8 weeks
Number of subjects: 12
Study: 7658535

Group type: EXPERIMENTAL
Intervention: Hypospadias patients
Number of subjects: 73

Group type: COMPARATOR
Intervention: Comparison subjects
Number of subjects: 73
Study: 2756879

Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 79760

Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (T.A.)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 31924551

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF Ultra
Number of subjects: 205

Group type: COMPARATOR
Intervention: Xpert MTB/RIF
Number of subjects: 205
Study: 30431575

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to quadriceps and gastrocnemius for 60 minutes, for up to 10 sessions.
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (standard care without NMES)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 59
Study: 27710263

Group type: EXPERIMENTAL
Intervention: Peginterferon lambda‐1a (Lambda) with ribavirin (RBV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peginterferon alfa‐2a (Alfa) with ribavirin (RBV)
Number of subjects: 0
Study: 25789311

Group type: EXPERIMENTAL
Intervention: Sacrocolpopexy during cystectomy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no sacrocolpopexy)
Number of subjects: 24
Study: 23595582

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) for 21 days from day 5 of menses
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tranexamic acid (TA) for 5 days from day 1 of menses
Number of subjects: 90
Study: 19863619

Group type: EXPERIMENTAL
Intervention: FPV 1400 mg bid with TDF 300 mg qd
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: FPV/RTV 700/100 mg bid with TDF 300 mg qd
Number of subjects: 36

Group type: COMPARATOR
Intervention: FPV 1400 mg bid without TDF
Number of subjects: 36

Group type: COMPARATOR
Intervention: FPV/RTV 700/100 mg bid without TDF
Number of subjects: 36
Study: 18661061

Group type: EXPERIMENTAL
Intervention: Rapid Palatal Expansion (RPE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Damon appliance
Number of subjects: 19
Study: 15679715

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 419

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study: 12893904

Group type: EXPERIMENTAL
Intervention: Undiluted direct injection of ferumoxides (0.56 mg of iron per kg of body weight, administered during 2 minutes at 2 mL/min)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Diluted slow infusion of ferumoxides (administered during 30 minutes)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Both interventions (direct injection and slow infusion)
Number of subjects: 233
Study: 10589310

Group type: EXPERIMENTAL
Intervention: teacher/self-preparation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: teacher/workshop
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: nurse/self-preparation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: nurse/workshop
Number of subjects: 100

Group type: COMPARATOR
Intervention: control
Number of subjects: 100
Study: 9005789

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg intravenous followed by 400 mg oral once a day for at least 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg oral once a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ofloxacin (various regimens: 200 mg thrice a day, 200 mg twice a day, 400 mg once a day)
Number of subjects: 0
Study: 1685055

Group type: EXPERIMENTAL
Intervention: Gamma-nail
Number of subjects: 100

Group type: COMPARATOR
Intervention: DHS
Number of subjects: 100
Study: 6781586

Group type: EXPERIMENTAL
Intervention: 50 mg/m2 (low dose)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 500 mg/m2 (medium dose)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 5 g/m2 (high dose)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cross-over to higher dose
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: High-dose regimen
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Patients who completed first four treatments
Number of subjects: 72
Study: 31622456

Group type: EXPERIMENTAL
Intervention: Early ART initiation during TB treatment
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Late ART initiation during TB treatment
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: Sequential ART initiation after TB treatment completion
Number of subjects: 642

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 642
Study: 30682067

Group type: EXPERIMENTAL
Intervention: TAU plus the employment of Voices, an online self‐training program for prosodic rehabilitation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment‐as‐usual (TAU)
Number of subjects: 50
Study: 28548619

Group type: EXPERIMENTAL
Intervention: Moti-4 intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 131
Study: 25268539

Group type: EXPERIMENTAL
Intervention: Playworks program (intervention group)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Single-day measurement (control group)
Number of subjects: 365
Study: 23522530

Group type: EXPERIMENTAL
Intervention: Phentolamine administered at 30 minutes after IAN block
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Phentolamine administered at 60 minutes after IAN block
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham injection at 30 minutes and phentolamine at 60 minutes
Number of subjects: 90

Group type: COMPARATOR
Intervention: Phentolamine at 30 minutes and sham at 60 minutes
Number of subjects: 90
Study: 22397236

Group type: EXPERIMENTAL
Intervention: Pilates training group (PTG; N = 34)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (CG; N = 27)
Number of subjects: 58
Study: 19267842

Group type: EXPERIMENTAL
Intervention: Topical hyaluronic acid (HA) gel preparation (0.2%)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 17539712

Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing (GPAP) performed in teeth instrumented 3 months earlier
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glycine powder air polishing (GPAP) performed in previously non‐instrumented teeth
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 60
Study: 14744178

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 20 mg/day, most receiving 5 to 10 mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11099053

Group type: EXPERIMENTAL
Intervention: 50 microg/ml hr-EGF
Number of subjects: 103

Group type: COMPARATOR
Intervention: 10 microg/ml hr-EGF
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 9254399

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 127
Study: 8445427

Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate (IT MTX)
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Cranial radiation (CXRT)
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: Intensive systemic therapy with either IT MTX or CXRT
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Standard systemic therapy with CXRT
Number of subjects: 1388

Group type: COMPARATOR
Intervention: Standard systemic therapy with IT MTX
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: CXRT in patients 10 years or older with intensive systemic therapy
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: IT MTX in patients 10 years or older with intensive systemic therapy
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: IT MTX in patients less than 10 years of age with intensive systemic therapy
Number of subjects: 1388

Group type: EXPERIMENTAL
Intervention: CXRT in patients less than 10 years of age with intensive systemic therapy
Number of subjects: 1388
Study: 3771022

Group type: EXPERIMENTAL
Intervention: Cordial substitution group (methadone-associated cordial)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard detoxification group
Number of subjects: 40
Study: 29788996

Group type: EXPERIMENTAL
Intervention: Guided web-based intervention with treatment as usual and immediate access to the web-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting control condition with treatment as usual and delayed access to the web-based intervention
Number of subjects: 0
Study: 27338551

Group type: EXPERIMENTAL
Intervention: Topical lidocaine spray (group L)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 322
Study: 25548768

Group type: EXPERIMENTAL
Intervention: Vinpocetine and pyritinol
Number of subjects: 30
Study: 22759255

Group type: EXPERIMENTAL
Intervention: SGP‐HA (≤1.5 mL/lip)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: SGP‐HA
Number of subjects: 180

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 180
Study: 20041473

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) with quinidine pre-treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dextromethorphan (DM) alone
Number of subjects: 8